HC Wainwright Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

Trevi Therapeutics (NASDAQ:TRVI) had its price objective increased by HC Wainwright from $6.00 to $7.50 in a research note published on Thursday morning, MarketBeat reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Trevi Therapeutics’ FY2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.40) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.49) EPS and FY2028 earnings at ($0.38) EPS.

A number of other analysts have also recently weighed in on the company. Leerink Partners started coverage on Trevi Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target on the stock. EF Hutton Acquisition Co. I raised Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. D. Boral Capital reissued a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a report on Thursday. B. Riley restated a “buy” rating and set a $6.00 price objective on shares of Trevi Therapeutics in a research report on Monday, October 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $8.00 price target on shares of Trevi Therapeutics in a research note on Thursday. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $9.31.

Trevi Therapeutics Stock Performance

Shares of NASDAQ TRVI opened at $3.60 on Thursday. The stock’s 50-day moving average is $2.96 and its two-hundred day moving average is $2.91. Trevi Therapeutics has a 1-year low of $1.22 and a 1-year high of $4.60.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter in the previous year, the business earned ($0.08) EPS. Sell-side analysts expect that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its position in Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after acquiring an additional 6,764 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in shares of Trevi Therapeutics during the first quarter worth $47,000. Intech Investment Management LLC acquired a new stake in shares of Trevi Therapeutics during the third quarter worth $63,000. Hsbc Holdings PLC purchased a new position in Trevi Therapeutics in the 2nd quarter valued at $61,000. Finally, SG Americas Securities LLC acquired a new position in Trevi Therapeutics in the 3rd quarter valued at $78,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.